Yujie Ke

Dr. Yujie Ke


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2022 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
YKYujie Ke
Yujie Ke
XMXin Ma
Xin Ma
YJYuanyuan Jing
Yuanyuan Jing
TDTongxiang Diao
Tongxiang Diao
LYLisheng Yu
Lisheng Yu

17 August 2021 in Current Medical Science
Verified
Journal Article
Open access
PDF file
XMXin Ma
Xin Ma
YKYujie Ke
Yujie Ke
YJYuan-Yuan Jing
Yuan-Yuan Jing
TDTong-Xiang Diao
Tong-Xiang Diao
LYLi-Sheng Yu
Li-Sheng Yu
Migraine is one of the most common and highest burdens of disease. As a primary cerebral dysfunction illness, migraine might exhibit other system-related symptoms, including vestibular and cochlear symptoms. With the publication of the diagnostic criteria of vestibular migraine, the link between migraine and vestibular symptoms became clear. However, the relationship between migraine and cochlear symptoms is far from straightforward. Therefore, we focus on the correlation between migraine and deafness, sudden sensorineural hearing loss, acute tinnitus, and chronic tinnitus to better understand the relationship between migraine and cochlear symptoms.

21 November 2023 in The Laryngoscope
Verified
Journal Article
Closed access
YKYujie Ke
Yujie Ke
XMXin Ma
Xin Ma
YJYuanyuan Jing
Yuanyuan Jing
TDTongxiang Diao
Tongxiang Diao
LYLisheng Yu
Lisheng Yu

17 March 2026 in Frontiers in Oral Health
Verified
Journal Article
Open access
PDF file
YKYujie Ke
Yujie Ke
ZHZhicong Hong
Zhicong Hong
LGLimei Guan
Limei Guan
XLXianyang Luo
Xianyang Luo
ZYZhenhong Ye
Zhenhong Ye
Objective: This study aimed to investigate the effect of preoperative neoadjuvant immunochemotherapy (NAICT) on the prognosis of patients with locally advanced oral squamous cell carcinomas (OSCC), thereby providing evidence-based guidance for the clinical management of OSCC. Methods: We conducted a retrospective cohort study of OSCC cases treated at our institution between 2017 and 2022. Kaplan–Meier survival curves, along with univariate and multivariate Cox regression analyses, were employed to identify independent factors influencing 3-year overall survival (OS) and disease-free survival (DFS) rates. Results: A total of 158 patients with locally advanced OSCC were included. 119 patients received simple surgical treatment, 15 patients underwent neoadjuvant chemotherapy (NAC) followed by surgery and 24 patients underwent NAICT followed by surgery. Multivariate analysis identified differentiation ( P = 0.041), negative margins ( P = 0.043), N stage ( P = 0.046), treatment strategy ( P = 0.016), postoperative recurrence ( P < 0.001), and postoperative metastasis ( P = 0.044) as independent factors influencing 3-year OS. For 3-year DFS, the independent factors included negative margins ( P = 0.017), N stage ( P = 0.006), treatment strategy ( P = 0.004), postoperative recurrence ( P < 0.001), and post-operative metastasis ( P < 0.001). Compared to direct surgery, surgery following NAC showed no significant difference in 3-year OS (53.3% vs. 57.1%, P = 0.701) and 3-year DFS (33.3% vs. 52.9%, P = 0.099). Compared to direct surgery, preoperative NAICT significantly improved 3-year OS (82.4% vs. 57.1%, P = 0.004) and 3-year DFS (83.3% vs. 52.9%, P = 0.007). Furthermore, compared to surgery following NAC, preoperative NAICT was associated with a significantly improved 3-year OS (82.4% vs. 53.3%, P = 0.03) and 3-year DFS (83.3% vs. 33.3%, P = 0.001). Treatment-related adverse events occurred in 70.8% of patients receiving NAICT. All events were grade 1–2 in severity and resolved following treatment. Conclusion: Compared to direct surgery or NAC followed by surgery, preoperative NAICT demonstrated a more favorable impact on the prognosis of patients with locally advanced OSCC, while exhibiting manageable treatment-related adverse effects.